| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Purpura, Thrombocytopenic, Idiopathic | 50 | 2024 | 232 | 18.290 |
Why?
|
| Thrombopoietin | 70 | 2024 | 223 | 17.010 |
Why?
|
| Receptors, Fc | 37 | 2024 | 540 | 10.970 |
Why?
|
| Thrombocytopenia | 52 | 2024 | 1171 | 9.620 |
Why?
|
| Recombinant Fusion Proteins | 38 | 2023 | 3770 | 6.800 |
Why?
|
| Receptors, Thrombopoietin | 31 | 2021 | 156 | 6.540 |
Why?
|
| Benzoates | 12 | 2020 | 217 | 3.600 |
Why?
|
| Hydrazines | 12 | 2020 | 220 | 3.600 |
Why?
|
| Platelet Count | 43 | 2023 | 780 | 3.580 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 8 | 2023 | 142 | 2.840 |
Why?
|
| Blood Platelets | 35 | 2023 | 2506 | 2.650 |
Why?
|
| Thrombopoiesis | 12 | 2021 | 153 | 2.410 |
Why?
|
| Gaucher Disease | 7 | 2020 | 112 | 2.380 |
Why?
|
| Hemin | 6 | 2015 | 49 | 2.090 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 5 | 2021 | 139 | 2.030 |
Why?
|
| Pyrazoles | 12 | 2020 | 1970 | 1.950 |
Why?
|
| Hematologic Agents | 3 | 2018 | 39 | 1.710 |
Why?
|
| Pregnancy Complications, Hematologic | 5 | 2024 | 183 | 1.640 |
Why?
|
| Megakaryocytes | 19 | 2014 | 542 | 1.370 |
Why?
|
| Antimalarials | 8 | 2017 | 903 | 1.180 |
Why?
|
| Receptors, Cytokine | 7 | 2001 | 261 | 1.160 |
Why?
|
| Hemorrhage | 11 | 2024 | 3461 | 1.110 |
Why?
|
| Anemia | 5 | 2024 | 1499 | 1.080 |
Why?
|
| Thiophenes | 6 | 2023 | 590 | 1.020 |
Why?
|
| Platelet Transfusion | 12 | 2022 | 314 | 0.970 |
Why?
|
| Hemoglobinuria, Paroxysmal | 2 | 2023 | 102 | 0.940 |
Why?
|
| Porphyria, Acute Intermittent | 2 | 2021 | 15 | 0.890 |
Why?
|
| Chloroquine | 2 | 2015 | 280 | 0.890 |
Why?
|
| Blood Preservation | 6 | 2018 | 177 | 0.870 |
Why?
|
| Polyethylene Glycols | 14 | 2011 | 1181 | 0.840 |
Why?
|
| Complement Inactivating Agents | 2 | 2023 | 50 | 0.830 |
Why?
|
| Morpholines | 2 | 2022 | 561 | 0.790 |
Why?
|
| Splenectomy | 8 | 2022 | 395 | 0.770 |
Why?
|
| Aminopyridines | 2 | 2022 | 541 | 0.760 |
Why?
|
| Thiazoles | 6 | 2023 | 1484 | 0.740 |
Why?
|
| Erythrocyte Transfusion | 3 | 2022 | 565 | 0.730 |
Why?
|
| Liver Diseases | 4 | 2021 | 1252 | 0.720 |
Why?
|
| Humans | 181 | 2024 | 742088 | 0.710 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2020 | 78 | 0.700 |
Why?
|
| Anemia, Aplastic | 1 | 2021 | 226 | 0.700 |
Why?
|
| von Willebrand Disease, Type 1 | 1 | 2019 | 5 | 0.690 |
Why?
|
| L-Lactate Dehydrogenase | 2 | 2019 | 424 | 0.690 |
Why?
|
| Protoporphyrins | 3 | 2015 | 164 | 0.680 |
Why?
|
| Glucosylceramidase | 1 | 2020 | 124 | 0.680 |
Why?
|
| Iron Overload | 1 | 2021 | 243 | 0.680 |
Why?
|
| Deamino Arginine Vasopressin | 1 | 2019 | 91 | 0.670 |
Why?
|
| Carrier Proteins | 8 | 2023 | 5019 | 0.660 |
Why?
|
| Antineoplastic Agents | 14 | 2022 | 13655 | 0.640 |
Why?
|
| Blood Platelet Disorders | 1 | 2018 | 58 | 0.640 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2018 | 188 | 0.620 |
Why?
|
| Recombinant Proteins | 19 | 2014 | 6608 | 0.620 |
Why?
|
| Anticoagulants | 10 | 2018 | 4595 | 0.620 |
Why?
|
| Immunoglobulin Fc Fragments | 1 | 2019 | 279 | 0.620 |
Why?
|
| Product Surveillance, Postmarketing | 3 | 2020 | 430 | 0.610 |
Why?
|
| Neoplasms | 16 | 2022 | 21596 | 0.590 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2019 | 314 | 0.570 |
Why?
|
| Adult | 66 | 2023 | 213712 | 0.570 |
Why?
|
| Autoimmunity | 3 | 2022 | 1348 | 0.570 |
Why?
|
| 1-Deoxynojirimycin | 2 | 2013 | 18 | 0.570 |
Why?
|
| Prothrombin | 3 | 2022 | 185 | 0.570 |
Why?
|
| Hematologic Neoplasms | 5 | 2022 | 1820 | 0.560 |
Why?
|
| Heparin | 4 | 2017 | 1636 | 0.560 |
Why?
|
| Hemangiosarcoma | 1 | 2018 | 236 | 0.550 |
Why?
|
| Bacterial Vaccines | 1 | 2018 | 402 | 0.550 |
Why?
|
| Middle Aged | 65 | 2022 | 213127 | 0.550 |
Why?
|
| Antifibrinolytic Agents | 1 | 2018 | 254 | 0.550 |
Why?
|
| Hemeproteins | 5 | 2017 | 62 | 0.540 |
Why?
|
| Neoplasm Proteins | 9 | 2001 | 3691 | 0.540 |
Why?
|
| Disease Susceptibility | 2 | 2019 | 1780 | 0.530 |
Why?
|
| Antiphospholipid Syndrome | 2 | 2014 | 173 | 0.520 |
Why?
|
| Molecular Dynamics Simulation | 2 | 2015 | 413 | 0.510 |
Why?
|
| Treatment Outcome | 28 | 2024 | 62966 | 0.510 |
Why?
|
| Plateletpheresis | 6 | 2004 | 47 | 0.500 |
Why?
|
| End Stage Liver Disease | 1 | 2019 | 314 | 0.500 |
Why?
|
| Pre-Eclampsia | 1 | 2024 | 1196 | 0.490 |
Why?
|
| Thrombosis | 7 | 2023 | 2966 | 0.490 |
Why?
|
| Complement C1s | 3 | 2023 | 11 | 0.480 |
Why?
|
| Perioperative Care | 2 | 2018 | 997 | 0.470 |
Why?
|
| Aged | 47 | 2022 | 162944 | 0.470 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 694 | 0.460 |
Why?
|
| Antibodies, Neutralizing | 2 | 2020 | 1970 | 0.460 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 3 | 2017 | 1675 | 0.460 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2021 | 657 | 0.450 |
Why?
|
| Oxazolidinones | 3 | 2003 | 96 | 0.450 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2020 | 131 | 0.450 |
Why?
|
| Female | 71 | 2024 | 379592 | 0.450 |
Why?
|
| Male | 74 | 2022 | 349538 | 0.440 |
Why?
|
| Immunoglobulin G | 3 | 2019 | 4554 | 0.440 |
Why?
|
| Viral Vaccines | 1 | 2018 | 636 | 0.440 |
Why?
|
| Reticulin | 2 | 2009 | 21 | 0.440 |
Why?
|
| Blood Donors | 5 | 2008 | 355 | 0.430 |
Why?
|
| Venous Thrombosis | 7 | 2016 | 1237 | 0.430 |
Why?
|
| Pyrimidines | 2 | 2022 | 2933 | 0.420 |
Why?
|
| Virus Diseases | 1 | 2018 | 710 | 0.420 |
Why?
|
| Acetamides | 3 | 2003 | 249 | 0.410 |
Why?
|
| Liver Transplantation | 2 | 2023 | 2117 | 0.410 |
Why?
|
| Proto-Oncogene Proteins | 7 | 2001 | 4553 | 0.400 |
Why?
|
| Dose-Response Relationship, Drug | 12 | 2018 | 10943 | 0.400 |
Why?
|
| Hepatitis C | 1 | 2021 | 1582 | 0.390 |
Why?
|
| Dimerization | 4 | 2014 | 893 | 0.390 |
Why?
|
| Oxazines | 2 | 2023 | 298 | 0.390 |
Why?
|
| Clinical Trials as Topic | 13 | 2021 | 7901 | 0.390 |
Why?
|
| Tungsten | 2 | 2021 | 16 | 0.390 |
Why?
|
| Combined Modality Therapy | 7 | 2021 | 8621 | 0.380 |
Why?
|
| Nephelometry and Turbidimetry | 1 | 2010 | 91 | 0.380 |
Why?
|
| Hemoglobins | 7 | 2021 | 1532 | 0.380 |
Why?
|
| Dalteparin | 3 | 2012 | 42 | 0.380 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2010 | 87 | 0.370 |
Why?
|
| Erythrocytes | 4 | 2022 | 2452 | 0.370 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2010 | 172 | 0.360 |
Why?
|
| Quality of Life | 10 | 2023 | 12730 | 0.360 |
Why?
|
| Bacterial Infections | 1 | 2018 | 1389 | 0.360 |
Why?
|
| Apoptosis | 6 | 2012 | 9715 | 0.360 |
Why?
|
| Heparin, Low-Molecular-Weight | 2 | 2002 | 339 | 0.350 |
Why?
|
| Colony-Stimulating Factors | 4 | 2013 | 216 | 0.350 |
Why?
|
| Hematology | 4 | 2019 | 219 | 0.350 |
Why?
|
| Thrombocythemia, Essential | 2 | 2020 | 103 | 0.350 |
Why?
|
| Plasmodium falciparum | 4 | 2017 | 1726 | 0.350 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2021 | 1847 | 0.340 |
Why?
|
| Thermodynamics | 4 | 2015 | 594 | 0.340 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2022 | 5522 | 0.330 |
Why?
|
| Liver Neoplasms | 5 | 2018 | 4249 | 0.330 |
Why?
|
| Postoperative Care | 1 | 2015 | 1484 | 0.320 |
Why?
|
| Hematopoietic Cell Growth Factors | 3 | 2008 | 102 | 0.320 |
Why?
|
| Retrospective Studies | 20 | 2023 | 77098 | 0.320 |
Why?
|
| Young Adult | 18 | 2021 | 56350 | 0.320 |
Why?
|
| Blood Cell Count | 5 | 2019 | 402 | 0.320 |
Why?
|
| Autoantibodies | 5 | 2023 | 2036 | 0.320 |
Why?
|
| Disease Management | 6 | 2021 | 2450 | 0.320 |
Why?
|
| Leukemia | 1 | 2016 | 1507 | 0.320 |
Why?
|
| Aged, 80 and over | 19 | 2022 | 57683 | 0.320 |
Why?
|
| Thrombin | 2 | 2012 | 598 | 0.310 |
Why?
|
| Quinolines | 1 | 2013 | 719 | 0.310 |
Why?
|
| Polycythemia Vera | 2 | 2019 | 163 | 0.310 |
Why?
|
| Red-Cell Aplasia, Pure | 1 | 2007 | 30 | 0.310 |
Why?
|
| Hemolysis | 4 | 2023 | 420 | 0.310 |
Why?
|
| Injections, Subcutaneous | 6 | 2013 | 664 | 0.300 |
Why?
|
| Blood Transfusion | 6 | 2021 | 1296 | 0.300 |
Why?
|
| Remission Induction | 3 | 2021 | 2384 | 0.290 |
Why?
|
| Protozoan Proteins | 1 | 2013 | 827 | 0.290 |
Why?
|
| Double-Blind Method | 9 | 2023 | 12017 | 0.290 |
Why?
|
| Anti-Infective Agents | 3 | 2003 | 971 | 0.280 |
Why?
|
| Self Administration | 2 | 2020 | 386 | 0.270 |
Why?
|
| Chronic Disease | 8 | 2019 | 9144 | 0.270 |
Why?
|
| Pipecolic Acids | 1 | 2006 | 76 | 0.270 |
Why?
|
| X-Ray Absorption Spectroscopy | 2 | 2015 | 5 | 0.260 |
Why?
|
| Primary Myelofibrosis | 1 | 2007 | 214 | 0.260 |
Why?
|
| Malaria, Falciparum | 2 | 2013 | 1071 | 0.260 |
Why?
|
| Ploidies | 6 | 1996 | 281 | 0.260 |
Why?
|
| Serum Albumin, Bovine | 2 | 2005 | 324 | 0.250 |
Why?
|
| Databases, Factual | 1 | 2020 | 7716 | 0.250 |
Why?
|
| Blood Coagulation | 3 | 2020 | 1126 | 0.250 |
Why?
|
| Registries | 1 | 2020 | 8077 | 0.240 |
Why?
|
| Time Factors | 15 | 2019 | 40054 | 0.240 |
Why?
|
| Pyridines | 3 | 2023 | 2818 | 0.240 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2019 | 5425 | 0.230 |
Why?
|
| Administration, Oral | 3 | 2022 | 3913 | 0.230 |
Why?
|
| Standard of Care | 2 | 2021 | 562 | 0.230 |
Why?
|
| Bone Marrow Cells | 11 | 2014 | 2513 | 0.230 |
Why?
|
| Spectrophotometry, Ultraviolet | 2 | 2014 | 220 | 0.230 |
Why?
|
| Water | 3 | 2014 | 1388 | 0.220 |
Why?
|
| Quinidine | 2 | 2015 | 57 | 0.220 |
Why?
|
| Quinine | 2 | 2015 | 54 | 0.220 |
Why?
|
| Neutropenia | 5 | 2013 | 891 | 0.220 |
Why?
|
| Catheterization, Central Venous | 2 | 2005 | 514 | 0.210 |
Why?
|
| Catheterization | 2 | 2005 | 1468 | 0.210 |
Why?
|
| Transplantation, Autologous | 1 | 2007 | 2123 | 0.210 |
Why?
|
| Porphyrias, Hepatic | 1 | 2021 | 7 | 0.210 |
Why?
|
| Platelet Factor 4 | 4 | 2017 | 129 | 0.210 |
Why?
|
| Stem Cell Transplantation | 2 | 2009 | 1618 | 0.210 |
Why?
|
| Stromal Cells | 1 | 2007 | 1353 | 0.210 |
Why?
|
| Follow-Up Studies | 7 | 2022 | 39004 | 0.210 |
Why?
|
| Hematopoiesis | 5 | 2001 | 2066 | 0.210 |
Why?
|
| Bone Marrow | 5 | 2010 | 2941 | 0.210 |
Why?
|
| Aminoquinolines | 2 | 2013 | 109 | 0.200 |
Why?
|
| Neutrophils | 3 | 2012 | 3711 | 0.200 |
Why?
|
| Bone Marrow Diseases | 2 | 2013 | 230 | 0.200 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 425 | 0.200 |
Why?
|
| Complement C5 | 1 | 2021 | 111 | 0.200 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2020 | 34 | 0.190 |
Why?
|
| Risk Reduction Behavior | 1 | 2008 | 1123 | 0.190 |
Why?
|
| Urate Oxidase | 1 | 2020 | 35 | 0.190 |
Why?
|
| Plaque, Atherosclerotic | 2 | 2022 | 1499 | 0.190 |
Why?
|
| Methemoglobinemia | 1 | 2020 | 44 | 0.190 |
Why?
|
| Glycogen Storage Disease Type I | 1 | 2020 | 53 | 0.190 |
Why?
|
| Drug Resistance | 2 | 2020 | 1608 | 0.190 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2017 | 3862 | 0.180 |
Why?
|
| Medication Errors | 1 | 2006 | 797 | 0.170 |
Why?
|
| Drug Tolerance | 1 | 2021 | 375 | 0.170 |
Why?
|
| Platelet Glycoprotein GPIb-IX Complex | 1 | 2020 | 141 | 0.170 |
Why?
|
| Blood Coagulation Tests | 2 | 2019 | 263 | 0.170 |
Why?
|
| Blood Component Transfusion | 2 | 2013 | 142 | 0.170 |
Why?
|
| Decision Trees | 2 | 2019 | 506 | 0.170 |
Why?
|
| Severity of Illness Index | 5 | 2021 | 15530 | 0.170 |
Why?
|
| Spectrometry, X-Ray Emission | 1 | 2019 | 144 | 0.170 |
Why?
|
| Ristocetin | 1 | 2018 | 26 | 0.170 |
Why?
|
| Hyperammonemia | 1 | 2020 | 76 | 0.170 |
Why?
|
| Abruptio Placentae | 1 | 2020 | 118 | 0.170 |
Why?
|
| Spectrophotometry | 3 | 2018 | 313 | 0.170 |
Why?
|
| Busulfan | 5 | 1999 | 262 | 0.170 |
Why?
|
| Normal Distribution | 1 | 2019 | 280 | 0.170 |
Why?
|
| Living Donors | 2 | 2023 | 618 | 0.160 |
Why?
|
| Skin Diseases | 1 | 2007 | 1065 | 0.160 |
Why?
|
| Early Diagnosis | 2 | 2020 | 1184 | 0.160 |
Why?
|
| Drug Substitution | 1 | 2021 | 281 | 0.160 |
Why?
|
| Ferritins | 1 | 2021 | 590 | 0.160 |
Why?
|
| Antigens, CD34 | 1 | 2000 | 657 | 0.160 |
Why?
|
| Hydroxyurea | 1 | 2019 | 290 | 0.160 |
Why?
|
| Animals | 34 | 2021 | 168561 | 0.160 |
Why?
|
| Pyruvate Metabolism, Inborn Errors | 1 | 2018 | 45 | 0.160 |
Why?
|
| Drug Administration Schedule | 4 | 2018 | 4929 | 0.150 |
Why?
|
| Adenosine Diphosphate | 1 | 2018 | 425 | 0.150 |
Why?
|
| Anemia, Hemolytic, Congenital Nonspherocytic | 1 | 2018 | 51 | 0.150 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2000 | 625 | 0.150 |
Why?
|
| Hydrogen Bonding | 2 | 2015 | 293 | 0.150 |
Why?
|
| ROC Curve | 3 | 2020 | 3528 | 0.150 |
Why?
|
| Hematologic Diseases | 1 | 2001 | 498 | 0.150 |
Why?
|
| Infusions, Intravenous | 2 | 2018 | 2271 | 0.150 |
Why?
|
| Arachidonic Acid | 1 | 2018 | 434 | 0.150 |
Why?
|
| Patient Compliance | 1 | 2008 | 2680 | 0.150 |
Why?
|
| Quality Assurance, Health Care | 1 | 2008 | 2211 | 0.150 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 1998 | 219 | 0.150 |
Why?
|
| Pyruvate Kinase | 1 | 2018 | 189 | 0.150 |
Why?
|
| Live Birth | 1 | 2020 | 512 | 0.140 |
Why?
|
| Temperature | 1 | 2003 | 2207 | 0.140 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 14720 | 0.140 |
Why?
|
| Platelet Aggregation | 2 | 2018 | 800 | 0.140 |
Why?
|
| Blood Coagulation Factors | 1 | 2019 | 355 | 0.140 |
Why?
|
| Arteriovenous Malformations | 1 | 2020 | 396 | 0.140 |
Why?
|
| Immunosuppressive Agents | 3 | 2021 | 4147 | 0.140 |
Why?
|
| Watchful Waiting | 1 | 2020 | 491 | 0.140 |
Why?
|
| Hemostatics | 1 | 2019 | 229 | 0.140 |
Why?
|
| Models, Biological | 6 | 2020 | 9581 | 0.140 |
Why?
|
| Lipoproteins | 1 | 2001 | 876 | 0.140 |
Why?
|
| Delphi Technique | 1 | 2019 | 778 | 0.140 |
Why?
|
| Genes, Dominant | 1 | 2019 | 880 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2021 | 9941 | 0.140 |
Why?
|
| Thrombophilia | 1 | 2018 | 305 | 0.140 |
Why?
|
| Mefloquine | 1 | 2015 | 55 | 0.140 |
Why?
|
| Consensus | 2 | 2019 | 2935 | 0.140 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 3497 | 0.130 |
Why?
|
| Jehovah's Witnesses | 1 | 2015 | 14 | 0.130 |
Why?
|
| Models, Chemical | 2 | 2009 | 626 | 0.130 |
Why?
|
| Multicenter Studies as Topic | 1 | 2020 | 1661 | 0.130 |
Why?
|
| Acetonitriles | 1 | 2015 | 52 | 0.130 |
Why?
|
| Solutions | 2 | 2014 | 426 | 0.130 |
Why?
|
| Zinc | 1 | 2019 | 683 | 0.130 |
Why?
|
| Lasers | 1 | 2019 | 952 | 0.130 |
Why?
|
| Abortion, Spontaneous | 1 | 2020 | 542 | 0.130 |
Why?
|
| Epinephrine | 1 | 2018 | 793 | 0.130 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2018 | 664 | 0.130 |
Why?
|
| von Willebrand Factor | 1 | 2019 | 668 | 0.130 |
Why?
|
| Growth Substances | 2 | 1994 | 783 | 0.120 |
Why?
|
| Antibodies | 2 | 2006 | 2459 | 0.120 |
Why?
|
| Siblings | 1 | 2019 | 854 | 0.120 |
Why?
|
| Adolescent | 9 | 2020 | 85649 | 0.120 |
Why?
|
| Rats | 15 | 2009 | 24265 | 0.120 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 4 | 2009 | 902 | 0.120 |
Why?
|
| Venous Thromboembolism | 3 | 2020 | 1668 | 0.120 |
Why?
|
| Receptors, Immunologic | 1 | 2000 | 1423 | 0.120 |
Why?
|
| Molecular Conformation | 1 | 2015 | 563 | 0.120 |
Why?
|
| Caspases | 3 | 2003 | 928 | 0.120 |
Why?
|
| Coordination Complexes | 1 | 2015 | 115 | 0.120 |
Why?
|
| Physicians | 3 | 2019 | 4554 | 0.120 |
Why?
|
| IgA Deficiency | 1 | 2013 | 43 | 0.120 |
Why?
|
| Ferric Compounds | 1 | 2015 | 374 | 0.120 |
Why?
|
| Signal Transduction | 3 | 2013 | 23387 | 0.110 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2019 | 1366 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 3 | 2021 | 9274 | 0.110 |
Why?
|
| Crotalid Venoms | 1 | 1992 | 28 | 0.110 |
Why?
|
| Fetal Blood | 1 | 2019 | 1317 | 0.110 |
Why?
|
| Protein Conformation | 1 | 2021 | 4013 | 0.110 |
Why?
|
| Rosette Formation | 1 | 2012 | 153 | 0.110 |
Why?
|
| Myeloid Cells | 1 | 2017 | 804 | 0.110 |
Why?
|
| Solubility | 1 | 2014 | 1083 | 0.110 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2012 | 114 | 0.110 |
Why?
|
| Coronary Artery Disease | 2 | 2022 | 6454 | 0.110 |
Why?
|
| Quantum Theory | 1 | 2012 | 70 | 0.110 |
Why?
|
| Molecular Structure | 2 | 2014 | 1907 | 0.110 |
Why?
|
| Fever | 2 | 2011 | 1612 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 7276 | 0.110 |
Why?
|
| Thromboembolism | 1 | 1999 | 983 | 0.110 |
Why?
|
| Fibrinolytic Agents | 1 | 2002 | 2156 | 0.100 |
Why?
|
| Drug Evaluation | 1 | 2013 | 637 | 0.100 |
Why?
|
| Boronic Acids | 2 | 2009 | 965 | 0.100 |
Why?
|
| Preoperative Care | 1 | 2021 | 2245 | 0.100 |
Why?
|
| Pregnancy | 5 | 2024 | 29087 | 0.100 |
Why?
|
| Diffusion | 1 | 2014 | 832 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2021 | 4211 | 0.100 |
Why?
|
| Gelsolin | 2 | 2003 | 190 | 0.100 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 3 | 2009 | 647 | 0.100 |
Why?
|
| Half-Life | 2 | 2010 | 658 | 0.100 |
Why?
|
| Bence Jones Protein | 1 | 2010 | 18 | 0.100 |
Why?
|
| Ferrous Compounds | 1 | 2011 | 42 | 0.100 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2018 | 1130 | 0.100 |
Why?
|
| Blood Protein Electrophoresis | 1 | 2010 | 73 | 0.100 |
Why?
|
| Hepatomegaly | 1 | 2010 | 85 | 0.100 |
Why?
|
| Myeloma Proteins | 1 | 2010 | 70 | 0.100 |
Why?
|
| Deoxycytidine | 1 | 2015 | 824 | 0.100 |
Why?
|
| Multiple Myeloma | 3 | 2020 | 5169 | 0.090 |
Why?
|
| Molecular Mimicry | 1 | 2011 | 201 | 0.090 |
Why?
|
| Patients | 1 | 2017 | 892 | 0.090 |
Why?
|
| Densitometry | 1 | 2010 | 156 | 0.090 |
Why?
|
| Pyrazines | 2 | 2009 | 1231 | 0.090 |
Why?
|
| Fatigue | 4 | 2022 | 1526 | 0.090 |
Why?
|
| Secondary Prevention | 3 | 2007 | 1520 | 0.090 |
Why?
|
| Diagnostic Self Evaluation | 1 | 2012 | 230 | 0.090 |
Why?
|
| Collagen | 1 | 2018 | 2684 | 0.090 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 2187 | 0.090 |
Why?
|
| Hemophilia A | 1 | 2013 | 351 | 0.090 |
Why?
|
| Quinacrine | 1 | 2009 | 24 | 0.090 |
Why?
|
| History, 20th Century | 2 | 2014 | 2739 | 0.090 |
Why?
|
| Necrosis | 2 | 2007 | 1643 | 0.090 |
Why?
|
| Caspase 3 | 2 | 2003 | 759 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 6347 | 0.090 |
Why?
|
| Intention to Treat Analysis | 1 | 2010 | 425 | 0.090 |
Why?
|
| Erythropoietin | 4 | 2001 | 724 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2000 | 3381 | 0.090 |
Why?
|
| Serum | 1 | 2010 | 212 | 0.090 |
Why?
|
| Oxygen | 3 | 2020 | 4169 | 0.080 |
Why?
|
| Anthelmintics | 1 | 2009 | 62 | 0.080 |
Why?
|
| Homocysteine | 2 | 2022 | 647 | 0.080 |
Why?
|
| Fibrinogen | 2 | 2022 | 894 | 0.080 |
Why?
|
| Recurrence | 3 | 2019 | 8333 | 0.080 |
Why?
|
| Oligosaccharides | 1 | 2011 | 414 | 0.080 |
Why?
|
| Cisplatin | 1 | 2015 | 1637 | 0.080 |
Why?
|
| Bone and Bones | 1 | 2019 | 2575 | 0.080 |
Why?
|
| Dengue | 1 | 2012 | 256 | 0.080 |
Why?
|
| Genetic Association Studies | 1 | 2018 | 2699 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2008 | 133 | 0.080 |
Why?
|
| Growth Inhibitors | 1 | 1990 | 385 | 0.080 |
Why?
|
| Cell Survival | 4 | 2004 | 5872 | 0.080 |
Why?
|
| Schistosoma mansoni | 1 | 2009 | 149 | 0.080 |
Why?
|
| Kazakhstan | 1 | 2008 | 14 | 0.080 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2018 | 2038 | 0.080 |
Why?
|
| Drug Design | 2 | 2007 | 1078 | 0.080 |
Why?
|
| Biomimetics | 1 | 2009 | 172 | 0.080 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 2 | 2020 | 425 | 0.080 |
Why?
|
| Kinetics | 3 | 2017 | 6474 | 0.080 |
Why?
|
| Liver | 3 | 2023 | 7470 | 0.080 |
Why?
|
| Paraproteinemias | 1 | 2010 | 247 | 0.080 |
Why?
|
| Models, Molecular | 3 | 2013 | 5454 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2020 | 5095 | 0.080 |
Why?
|
| Infant, Newborn | 2 | 2021 | 25575 | 0.080 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 1864 | 0.080 |
Why?
|
| Hypertension | 1 | 2008 | 8455 | 0.080 |
Why?
|
| Pain | 2 | 2021 | 4961 | 0.080 |
Why?
|
| Janus Kinase 2 | 1 | 2010 | 527 | 0.070 |
Why?
|
| ADAM Proteins | 1 | 2009 | 242 | 0.070 |
Why?
|
| Cell Separation | 2 | 1992 | 1749 | 0.070 |
Why?
|
| Membrane Transport Proteins | 1 | 2013 | 1028 | 0.070 |
Why?
|
| Organometallic Compounds | 1 | 2011 | 665 | 0.070 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 3611 | 0.070 |
Why?
|
| Protein Biosynthesis | 1 | 1994 | 2126 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2013 | 1269 | 0.070 |
Why?
|
| Transforming Growth Factor beta | 2 | 1992 | 2006 | 0.070 |
Why?
|
| Anesthesia, Conduction | 1 | 2010 | 238 | 0.070 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2011 | 1351 | 0.070 |
Why?
|
| Enzyme Activation | 3 | 2003 | 3701 | 0.070 |
Why?
|
| Predictive Value of Tests | 2 | 2022 | 15056 | 0.070 |
Why?
|
| Glycoproteins | 1 | 1994 | 2260 | 0.070 |
Why?
|
| Medical History Taking | 1 | 2010 | 783 | 0.070 |
Why?
|
| Interleukin-6 | 3 | 2022 | 3199 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2018 | 2211 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2018 | 11472 | 0.070 |
Why?
|
| Benzimidazoles | 1 | 2011 | 848 | 0.070 |
Why?
|
| Protein Binding | 3 | 2010 | 9387 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2019 | 3439 | 0.070 |
Why?
|
| Acute Disease | 1 | 2016 | 7141 | 0.070 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2007 | 282 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 2 | 2009 | 700 | 0.070 |
Why?
|
| Peptides | 2 | 2009 | 4392 | 0.070 |
Why?
|
| Mortality | 1 | 2017 | 2857 | 0.070 |
Why?
|
| Prospective Studies | 6 | 2021 | 53187 | 0.070 |
Why?
|
| Lung Neoplasms | 2 | 2007 | 13019 | 0.070 |
Why?
|
| N-Acetylneuraminic Acid | 2 | 2023 | 177 | 0.070 |
Why?
|
| Rabbits | 4 | 1996 | 4886 | 0.070 |
Why?
|
| Heart Valve Diseases | 1 | 2013 | 1067 | 0.070 |
Why?
|
| Intraoperative Complications | 1 | 2012 | 1188 | 0.060 |
Why?
|
| Probability | 1 | 2010 | 2502 | 0.060 |
Why?
|
| Cells, Cultured | 8 | 2000 | 19223 | 0.060 |
Why?
|
| Inflammation | 2 | 2022 | 10578 | 0.060 |
Why?
|
| Cytochalasin B | 1 | 2004 | 74 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2013 | 227 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2003 | 1434 | 0.060 |
Why?
|
| Treatment Failure | 1 | 2010 | 2615 | 0.060 |
Why?
|
| Radioimmunoassay | 1 | 2005 | 918 | 0.060 |
Why?
|
| Egtazic Acid | 1 | 2004 | 173 | 0.060 |
Why?
|
| Myeloproliferative Disorders | 1 | 2010 | 603 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 2 | 2022 | 1483 | 0.060 |
Why?
|
| Mutation | 2 | 2019 | 29717 | 0.060 |
Why?
|
| Protease Inhibitors | 2 | 2009 | 790 | 0.060 |
Why?
|
| History, 17th Century | 1 | 2004 | 111 | 0.060 |
Why?
|
| Caspase 2 | 1 | 2003 | 27 | 0.060 |
Why?
|
| Amyloidosis | 1 | 2010 | 795 | 0.060 |
Why?
|
| Patient Selection | 2 | 2013 | 4214 | 0.060 |
Why?
|
| Tissue Adhesives | 1 | 2005 | 179 | 0.060 |
Why?
|
| Logistic Models | 1 | 2018 | 13403 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2018 | 15244 | 0.060 |
Why?
|
| Prognosis | 3 | 2021 | 29010 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2014 | 3760 | 0.060 |
Why?
|
| Complement Pathway, Classical | 1 | 2023 | 97 | 0.060 |
Why?
|
| Bupropion | 1 | 2005 | 303 | 0.060 |
Why?
|
| Aortic Valve | 1 | 2013 | 1911 | 0.060 |
Why?
|
| Caspase 9 | 1 | 2003 | 188 | 0.060 |
Why?
|
| Thrombocytosis | 2 | 1996 | 81 | 0.060 |
Why?
|
| Neuraminidase | 1 | 2023 | 210 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 1 | 2011 | 1167 | 0.050 |
Why?
|
| Prevalence | 1 | 2019 | 15194 | 0.050 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2013 | 1527 | 0.050 |
Why?
|
| Plasma | 1 | 2006 | 575 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2005 | 627 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 12344 | 0.050 |
Why?
|
| Endothelium, Vascular | 2 | 2009 | 4455 | 0.050 |
Why?
|
| Safety | 3 | 2001 | 1185 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3130 | 0.050 |
Why?
|
| Glycomics | 1 | 2023 | 121 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3236 | 0.050 |
Why?
|
| Ribosomes | 2 | 1976 | 499 | 0.050 |
Why?
|
| Arginine | 1 | 2006 | 944 | 0.050 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2005 | 503 | 0.050 |
Why?
|
| Acetylgalactosamine | 1 | 2021 | 37 | 0.050 |
Why?
|
| Blood Loss, Surgical | 2 | 2018 | 656 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2003 | 411 | 0.050 |
Why?
|
| Fat Substitutes | 1 | 2001 | 4 | 0.050 |
Why?
|
| Donor Selection | 1 | 2023 | 201 | 0.050 |
Why?
|
| Food Additives | 1 | 2001 | 19 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2005 | 1030 | 0.050 |
Why?
|
| Child, Preschool | 3 | 2018 | 40955 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2010 | 2107 | 0.050 |
Why?
|
| Coronary Vessels | 2 | 2022 | 3099 | 0.050 |
Why?
|
| Complement C3 | 1 | 2023 | 460 | 0.050 |
Why?
|
| Blood Proteins | 2 | 2009 | 1122 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2003 | 316 | 0.050 |
Why?
|
| Hemostasis | 1 | 2023 | 458 | 0.050 |
Why?
|
| Coronary Angiography | 2 | 2022 | 4567 | 0.050 |
Why?
|
| Phenotype | 1 | 2018 | 16331 | 0.050 |
Why?
|
| Reference Values | 2 | 2018 | 4982 | 0.050 |
Why?
|
| Flow Cytometry | 4 | 2000 | 5975 | 0.050 |
Why?
|
| Sucrose | 1 | 2001 | 164 | 0.050 |
Why?
|
| Bile Acids and Salts | 1 | 2022 | 353 | 0.050 |
Why?
|
| Cattle | 2 | 2005 | 3923 | 0.050 |
Why?
|
| Headache | 2 | 2014 | 1219 | 0.050 |
Why?
|
| Vancomycin | 1 | 2003 | 500 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 4 | 1997 | 8300 | 0.050 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2000 | 49 | 0.050 |
Why?
|
| Premedication | 2 | 2013 | 257 | 0.050 |
Why?
|
| Culture Media | 2 | 1994 | 902 | 0.050 |
Why?
|
| Digestive System | 1 | 2001 | 251 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 2 | 2022 | 2637 | 0.040 |
Why?
|
| Platelet Function Tests | 1 | 2001 | 270 | 0.040 |
Why?
|
| Synchrotrons | 1 | 2019 | 38 | 0.040 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2006 | 189 | 0.040 |
Why?
|
| Pulmonary Embolism | 2 | 2016 | 2370 | 0.040 |
Why?
|
| Multienzyme Complexes | 1 | 2003 | 686 | 0.040 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 3766 | 0.040 |
Why?
|
| Anesthesiology | 1 | 2010 | 1043 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 2021 | 342 | 0.040 |
Why?
|
| Plasma Exchange | 1 | 2020 | 155 | 0.040 |
Why?
|
| Biopsy | 2 | 2010 | 6756 | 0.040 |
Why?
|
| Warfarin | 2 | 2004 | 1493 | 0.040 |
Why?
|
| Molecular Weight | 1 | 2001 | 2255 | 0.040 |
Why?
|
| Child | 5 | 2018 | 77478 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 839 | 0.040 |
Why?
|
| Interleukin-11 | 1 | 1999 | 62 | 0.040 |
Why?
|
| Ammonia | 1 | 2020 | 239 | 0.040 |
Why?
|
| Cyclosporine | 1 | 2001 | 784 | 0.040 |
Why?
|
| Umbilical Veins | 1 | 1999 | 433 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 947 | 0.040 |
Why?
|
| Polypharmacy | 1 | 2001 | 294 | 0.040 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2001 | 341 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 683 | 0.040 |
Why?
|
| Models, Theoretical | 1 | 2010 | 3584 | 0.040 |
Why?
|
| Blood Banks | 1 | 1999 | 110 | 0.040 |
Why?
|
| Risk Factors | 7 | 2022 | 72145 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2020 | 418 | 0.040 |
Why?
|
| Pneumonectomy | 1 | 2005 | 1093 | 0.040 |
Why?
|
| Hemostasis, Surgical | 1 | 2018 | 128 | 0.040 |
Why?
|
| Hypercalcemia | 1 | 2020 | 405 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2004 | 1679 | 0.040 |
Why?
|
| Reticulocytes | 1 | 2018 | 290 | 0.040 |
Why?
|
| Methionine | 1 | 2000 | 590 | 0.040 |
Why?
|
| Transplantation Immunology | 1 | 2000 | 547 | 0.040 |
Why?
|
| False Negative Reactions | 1 | 2018 | 587 | 0.040 |
Why?
|
| Enzyme Inhibitors | 2 | 2011 | 3800 | 0.040 |
Why?
|
| Art | 1 | 1998 | 65 | 0.040 |
Why?
|
| Proteoglycans | 1 | 2000 | 834 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2006 | 2205 | 0.040 |
Why?
|
| Macrophages | 1 | 2012 | 5655 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2020 | 592 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 1916 | 0.040 |
Why?
|
| Gene Expression | 3 | 2000 | 7790 | 0.040 |
Why?
|
| Prednisone | 1 | 2001 | 1567 | 0.040 |
Why?
|
| RNA, Messenger | 4 | 2000 | 13029 | 0.040 |
Why?
|
| Polysaccharides | 1 | 2023 | 1051 | 0.040 |
Why?
|
| Postthrombotic Syndrome | 1 | 2016 | 28 | 0.040 |
Why?
|
| Alkaline Phosphatase | 1 | 2020 | 865 | 0.040 |
Why?
|
| Cell Division | 3 | 1994 | 4564 | 0.040 |
Why?
|
| Crystallization | 1 | 2017 | 525 | 0.030 |
Why?
|
| Protein Engineering | 1 | 2000 | 541 | 0.030 |
Why?
|
| Sulfonamides | 1 | 2006 | 1932 | 0.030 |
Why?
|
| Primates | 1 | 1999 | 543 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2013 | 3133 | 0.030 |
Why?
|
| Cinchona Alkaloids | 1 | 2015 | 1 | 0.030 |
Why?
|
| Transfection | 3 | 2000 | 5892 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2018 | 981 | 0.030 |
Why?
|
| Cell Nucleolus | 1 | 1976 | 166 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2002 | 995 | 0.030 |
Why?
|
| Ligands | 1 | 2023 | 3293 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 1997 | 319 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2001 | 2030 | 0.030 |
Why?
|
| Cholesterol, HDL | 1 | 2022 | 1813 | 0.030 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2000 | 2552 | 0.030 |
Why?
|
| Mitosis | 2 | 1992 | 1208 | 0.030 |
Why?
|
| History, 19th Century | 1 | 1998 | 720 | 0.030 |
Why?
|
| GPI-Linked Proteins | 2 | 1994 | 434 | 0.030 |
Why?
|
| Tunica Intima | 1 | 1997 | 464 | 0.030 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1999 | 627 | 0.030 |
Why?
|
| Epitopes | 1 | 2001 | 2569 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2000 | 1118 | 0.030 |
Why?
|
| X-Ray Diffraction | 1 | 2015 | 420 | 0.030 |
Why?
|
| Leukopenia | 1 | 1995 | 208 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2008 | 8297 | 0.030 |
Why?
|
| Goats | 1 | 1994 | 172 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 2000 | 4322 | 0.030 |
Why?
|
| Cell Death | 1 | 2000 | 1695 | 0.030 |
Why?
|
| Ribosomal Proteins | 1 | 1976 | 360 | 0.030 |
Why?
|
| Fibrosis | 1 | 2021 | 2026 | 0.030 |
Why?
|
| Phagocytosis | 1 | 2000 | 1538 | 0.030 |
Why?
|
| Immune Sera | 1 | 1994 | 641 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2020 | 1265 | 0.030 |
Why?
|
| Proteins | 4 | 1994 | 6096 | 0.030 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 1860 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 438 | 0.030 |
Why?
|
| Cytokines | 2 | 2021 | 7317 | 0.030 |
Why?
|
| United States | 6 | 2019 | 69693 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2019 | 1533 | 0.030 |
Why?
|
| Epistaxis | 1 | 2014 | 111 | 0.030 |
Why?
|
| Erythropoiesis | 2 | 2001 | 705 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2005 | 2068 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2000 | 1835 | 0.030 |
Why?
|
| Hemagglutination | 1 | 1992 | 34 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2000 | 4751 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2001 | 1806 | 0.030 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2012 | 25 | 0.030 |
Why?
|
| Medical Oncology | 2 | 2017 | 2235 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 21821 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 2203 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 19862 | 0.030 |
Why?
|
| Antithrombin Proteins | 1 | 2011 | 9 | 0.030 |
Why?
|
| Drugs, Investigational | 1 | 2014 | 214 | 0.030 |
Why?
|
| Sulfuric Acids | 1 | 1971 | 37 | 0.030 |
Why?
|
| Sheep | 1 | 1994 | 1437 | 0.030 |
Why?
|
| Myocardial Infarction | 1 | 2013 | 11690 | 0.030 |
Why?
|
| Cesarean Section | 1 | 2020 | 1363 | 0.020 |
Why?
|
| Ruthenium | 1 | 2011 | 22 | 0.020 |
Why?
|
| Protein Denaturation | 1 | 1971 | 237 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2008 | 4551 | 0.020 |
Why?
|
| Infant | 1 | 2013 | 35070 | 0.020 |
Why?
|
| Economics, Pharmaceutical | 1 | 2011 | 87 | 0.020 |
Why?
|
| Hydroxyl Radical | 1 | 2011 | 78 | 0.020 |
Why?
|
| Detergents | 1 | 1971 | 230 | 0.020 |
Why?
|
| Placenta | 1 | 2020 | 1694 | 0.020 |
Why?
|
| Transcription, Genetic | 3 | 1995 | 7721 | 0.020 |
Why?
|
| Electrochemistry | 1 | 2011 | 145 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 9185 | 0.020 |
Why?
|
| Binding Sites | 2 | 2011 | 6115 | 0.020 |
Why?
|
| Perioperative Period | 1 | 2012 | 256 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2023 | 2978 | 0.020 |
Why?
|
| Hemorrhagic Disorders | 1 | 2010 | 36 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2000 | 6452 | 0.020 |
Why?
|
| Sleep Disorders, Intrinsic | 1 | 2010 | 15 | 0.020 |
Why?
|
| Hospitalization | 2 | 2020 | 10232 | 0.020 |
Why?
|
| Carotid Stenosis | 1 | 1997 | 854 | 0.020 |
Why?
|
| Algorithms | 1 | 2010 | 13853 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2011 | 625 | 0.020 |
Why?
|
| Artifacts | 1 | 2018 | 1903 | 0.020 |
Why?
|
| Parasite Egg Count | 1 | 2009 | 27 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 4187 | 0.020 |
Why?
|
| Forecasting | 1 | 1999 | 2948 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2021 | 40450 | 0.020 |
Why?
|
| Inpatients | 1 | 2001 | 2495 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2001 | 11470 | 0.020 |
Why?
|
| Anemia, Sickle Cell | 1 | 1997 | 1017 | 0.020 |
Why?
|
| Risk Assessment | 3 | 2011 | 23320 | 0.020 |
Why?
|
| Molecular Sequence Data | 4 | 1995 | 18112 | 0.020 |
Why?
|
| Filgrastim | 1 | 2009 | 132 | 0.020 |
Why?
|
| Schistosomiasis mansoni | 1 | 2009 | 85 | 0.020 |
Why?
|
| Medicine | 1 | 2017 | 941 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2011 | 5385 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 1997 | 2128 | 0.020 |
Why?
|
| Interphase | 1 | 2008 | 224 | 0.020 |
Why?
|
| Thrombospondins | 1 | 2009 | 197 | 0.020 |
Why?
|
| Decision Making | 1 | 2002 | 3869 | 0.020 |
Why?
|
| Professional Practice | 1 | 2010 | 326 | 0.020 |
Why?
|
| Polyneuropathies | 1 | 2009 | 139 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1991 | 794 | 0.020 |
Why?
|
| Critical Illness | 1 | 2020 | 2665 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 3 | 1995 | 5867 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 6483 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2009 | 1159 | 0.020 |
Why?
|
| Mice | 4 | 2021 | 81045 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 4801 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 1988 | 206 | 0.020 |
Why?
|
| Echocardiography | 1 | 2020 | 5097 | 0.020 |
Why?
|
| Leukemia, Monocytic, Acute | 1 | 2006 | 58 | 0.020 |
Why?
|
| Karyotyping | 1 | 2008 | 1243 | 0.020 |
Why?
|
| Fluorescence Resonance Energy Transfer | 1 | 2009 | 401 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 3 | 1987 | 1801 | 0.020 |
Why?
|
| Complementary Therapies | 1 | 2010 | 484 | 0.020 |
Why?
|
| Lipids | 1 | 2017 | 3302 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2011 | 2014 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 1799 | 0.020 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 1527 | 0.020 |
Why?
|
| Critical Care | 1 | 1998 | 2640 | 0.020 |
Why?
|
| Membrane Glycoproteins | 2 | 1994 | 3769 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2020 | 12958 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2011 | 2187 | 0.020 |
Why?
|
| Point Mutation | 1 | 2010 | 1624 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 1995 | 12071 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 1991 | 1337 | 0.020 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 1 | 2006 | 272 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 1791 | 0.020 |
Why?
|
| Education, Medical, Continuing | 1 | 2010 | 839 | 0.020 |
Why?
|
| Bleeding Time | 1 | 2004 | 89 | 0.020 |
Why?
|
| Observer Variation | 1 | 2010 | 2593 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2010 | 3067 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2010 | 1181 | 0.010 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2006 | 233 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 13921 | 0.010 |
Why?
|
| Nerve Block | 1 | 2010 | 640 | 0.010 |
Why?
|
| Gastrointestinal Tract | 1 | 2009 | 814 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 3471 | 0.010 |
Why?
|
| Papio | 1 | 2004 | 656 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1994 | 13814 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2008 | 2638 | 0.010 |
Why?
|
| Lung | 1 | 2020 | 9826 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 15108 | 0.010 |
Why?
|
| Hip Prosthesis | 1 | 1988 | 917 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 2005 | 1583 | 0.010 |
Why?
|
| Food Industry | 1 | 2001 | 68 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2008 | 2751 | 0.010 |
Why?
|
| Cold Temperature | 1 | 2004 | 774 | 0.010 |
Why?
|
| Cysteine Endopeptidases | 1 | 2003 | 563 | 0.010 |
Why?
|
| Pandemics | 1 | 2020 | 8328 | 0.010 |
Why?
|
| Lymphoma, B-Cell | 1 | 2006 | 930 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 2 | 2011 | 7153 | 0.010 |
Why?
|
| Incidence | 1 | 2017 | 20928 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2020 | 35342 | 0.010 |
Why?
|
| HeLa Cells | 2 | 1976 | 3127 | 0.010 |
Why?
|
| Calcium | 1 | 1991 | 5753 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2009 | 3038 | 0.010 |
Why?
|
| Base Sequence | 3 | 1995 | 12797 | 0.010 |
Why?
|
| Societies, Medical | 1 | 2010 | 3740 | 0.010 |
Why?
|
| Telephone | 1 | 2001 | 617 | 0.010 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 1997 | 180 | 0.010 |
Why?
|
| Carotid Artery Injuries | 1 | 1997 | 96 | 0.010 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2003 | 1333 | 0.010 |
Why?
|
| Carotid Artery, Common | 1 | 1997 | 183 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2003 | 1949 | 0.010 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2006 | 1596 | 0.010 |
Why?
|
| Pediatrics | 1 | 2010 | 3462 | 0.010 |
Why?
|
| Centrifugation, Density Gradient | 1 | 1974 | 313 | 0.010 |
Why?
|
| Cross Infection | 1 | 2003 | 1413 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 5163 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1997 | 1183 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2012 | 21719 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 9410 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2001 | 1581 | 0.010 |
Why?
|
| Growth Hormone | 1 | 1995 | 703 | 0.010 |
Why?
|
| Chick Embryo | 1 | 1974 | 981 | 0.010 |
Why?
|
| Aspirin | 1 | 2004 | 3278 | 0.010 |
Why?
|
| Sulfur Isotopes | 1 | 1971 | 24 | 0.010 |
Why?
|
| Galactosidases | 1 | 1971 | 56 | 0.010 |
Why?
|
| Dialysis | 1 | 1971 | 75 | 0.010 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1993 | 708 | 0.010 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 1971 | 52 | 0.010 |
Why?
|
| Transferases | 1 | 1971 | 75 | 0.010 |
Why?
|
| RNA Nucleotidyltransferases | 1 | 1971 | 64 | 0.010 |
Why?
|
| Data Collection | 1 | 2001 | 3339 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1971 | 240 | 0.010 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1971 | 305 | 0.010 |
Why?
|
| Ultracentrifugation | 1 | 1971 | 182 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2010 | 15494 | 0.010 |
Why?
|
| Methods | 1 | 1971 | 1128 | 0.010 |
Why?
|
| Genes | 1 | 1995 | 1892 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1971 | 668 | 0.010 |
Why?
|
| Filtration | 1 | 1971 | 234 | 0.010 |
Why?
|
| Trypsin | 1 | 1971 | 509 | 0.010 |
Why?
|
| Cricetinae | 1 | 1974 | 2471 | 0.010 |
Why?
|
| Species Specificity | 1 | 1974 | 2479 | 0.010 |
Why?
|
| Plasmids | 1 | 1995 | 2305 | 0.010 |
Why?
|
| Urea | 1 | 1971 | 449 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 1971 | 574 | 0.010 |
Why?
|
| Neoplasms, Experimental | 1 | 1974 | 1274 | 0.010 |
Why?
|
| Public Health | 1 | 2001 | 2594 | 0.000 |
Why?
|
| Body Mass Index | 1 | 2005 | 12695 | 0.000 |
Why?
|
| Immunosorbent Techniques | 1 | 1987 | 184 | 0.000 |
Why?
|
| Thrombophlebitis | 1 | 1988 | 309 | 0.000 |
Why?
|
| Chromosome Deletion | 1 | 1991 | 1400 | 0.000 |
Why?
|
| Organ Specificity | 1 | 1991 | 2003 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 2191 | 0.000 |
Why?
|
| Tumor Cells, Cultured | 1 | 1993 | 6313 | 0.000 |
Why?
|
| Fibroblasts | 1 | 1995 | 4143 | 0.000 |
Why?
|
| Cytoplasmic Granules | 1 | 1987 | 610 | 0.000 |
Why?
|
| Polymers | 1 | 1971 | 1618 | 0.000 |
Why?
|
| Glycosaminoglycans | 1 | 1987 | 624 | 0.000 |
Why?
|
| Polymerase Chain Reaction | 1 | 1993 | 6171 | 0.000 |
Why?
|
| Microscopy, Electron | 1 | 1987 | 2645 | 0.000 |
Why?
|
| Cytoplasm | 1 | 1987 | 1539 | 0.000 |
Why?
|
| Cell Line | 1 | 1974 | 15994 | 0.000 |
Why?
|
| Kidney | 1 | 1974 | 7167 | 0.000 |
Why?
|
| Nuclear Proteins | 1 | 1993 | 5851 | 0.000 |
Why?
|
| DNA | 1 | 1991 | 7289 | 0.000 |
Why?
|
| DNA-Binding Proteins | 1 | 1993 | 9639 | 0.000 |
Why?
|